323 filings
Page 2 of 17
D
nldz1e8unmyf5w jj
12 Feb 24
$49.99 mm in equity / options, sold $49.99 mm, 11 investors
12:08pm
8-K
rjrb4as4fd9t
29 Jan 24
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
8:02am
S-8
1ezrayv0cpsul3et1
21 Dec 23
Registration of securities for employees
7:07pm
8-K
sv5xfeeo8 la68hhji
5 Dec 23
Entry into a Material Definitive Agreement
5:04pm
8-K
puzpo5fll5
6 Nov 23
Amendments to Articles of Incorporation or Bylaws
8:21pm
DEF 14C
nxk247 1712ef
16 Oct 23
Information statement
6:16pm
8-K
q8wv99
3 Oct 23
Departure of Directors or Certain Officers
4:34pm
PRE 14C
kkzy usgz9b
3 Oct 23
Preliminary information
4:12pm
8-K
wxaco9z
7 Sep 23
Skye Bioscience Reverse Stock Split to be Effective on September 8th
1:15pm
8-K/A
4nqlfw6w
1 Sep 23
Departure of Directors or Certain Officers
12:00am
D
svhlq0 ku
29 Aug 23
$62.25 mm in equity / debt / options / securities to be acquired, sold $62.25 mm, 12 investors
4:56pm
8-K
1ancs
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K/A
kg0qyfh ai9b05e
27 Mar 23
Departure of Directors or Certain Officers
4:09pm
8-K
t8lo7 bkpxixbykjx6
23 Feb 23
Entry into a Material Definitive Agreement
5:18pm
8-K
oumtuygps657gb
16 Feb 23
Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors
5:16pm
8-K
rnp6cz px829do1
15 Feb 23
Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5.60M Closing Payment
4:26pm